Diligence memo · auto-generated · as of July 2, 2026
Pathfinder Oncology, Inc.
Pathfinder Oncology, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Pathfinder Oncology, Inc. operates in Pharma, based in RALEIGH.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Pathfinder Oncology, Inc. has raised $4.0M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $4.0M on 2024-05-30.
Most recent recorded round closed around 2024-05-30.
Valuation (modeled)modeled
Provath models Pathfinder Oncology, Inc. at approximately $20M (range $3.0M–$54M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.47× the median modeled value of Seed Pharma companies in 2022–2024 (18 peers) — value vs value, same stage and era. Within the normal band (147% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 2.1 yr ago; this sector typically re-raises about every 16 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 52% of Pharma peers (310 compared).
Modeled value ranks above 44% of those peers.
Closest niche peers: Seal Rock Therapeutics, Inc., Diligent Pharma, Inc., A28 Therapeutics, Inc., Centaurus Therapeutics, Inc., Arcade Therapeutics, Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.